Figshare
2021
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
preprint
Dataset for the paper: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
Frontiers in Psychiatry
2021
Özden Merve Mollaahmetoğlu, Johanna Keeler, Katherine J Ashbullby et al.
62 citations
Background: The therapeutic benefits of ketamine have been demonstrated for a variety of psychiatric disorders. However, the role of ketamine induced psychoactive experiences in mediating the therapeutic effects is unclear. Despite the growing quantitative research on the efficacy of ketamine treatment, very few studies examined participant experiences of ketamine infusions in a treatment...
Journal of Affective Disorders
December 29, 2020
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.
BACKGROUND Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use. METHODS Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV...
The International Journal of Neuropsychopharmacology
December 29, 2020
Mu-Hong Chen, Wan-Chen Chang, Wei-Chen Lin et al.
28 citations
Frontostriatal disconnectivity plays a crucial role in the pathophysiology of major depressive disorder. However, whether the baseline functional connectivity of the frontostriatal network could predict the treatment outcome of low-dose ketamine infusion remains unknown. In total, 48 patients with treatment-resistant depression were randomly divided into 3 treatment groups (a single-dose...
Brain Research Bulletin
December 22, 2020
D. D. Vecchia, L. Kanazawa, E. Wendler et al.
The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment. Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has been shown to be effective in patients with treatment-resistant major depression. Thus, the present study evaluated the action of ketamine on memory impairment and depressive-like behavior...
Nature Communications
December 22, 2020
Elizabeth D. Ballard, Carlos A. Zarate
10 citations
Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. Ketamine also has short term dissociative effects, in which individuals report altered consciousness and perceptions of themselves and their environment. However, whether ketamine's dissociative side effects are necessary for its antidepressant effects remains unclear. This perspective...
Trends in Neurosciences
December 21, 2020
Neil K. Savalia, Ling-Xiao Shao, Alex C. Kwan
110 citations
Pilot studies have hinted that serotonergic psychedelics such as psilocybin may relieve depression, and could possibly do so by promoting neural plasticity. Intriguingly, another psychotomimetic compound, ketamine, is a fast-acting antidepressant and induces synapse formation. The similarities in behavioral and neural effects have been puzzling because the compounds target distinct molecular...
Brazilian Journal of Medical and Biological Research
December 18, 2020
G.S.B. Viana, E.M. Do Vale, Ana Giullia de Alencar Araújo et al.
Ketamine (KET) is an N-methyl-D-aspartate (NMDA) antagonist with rapid and long-lasting antidepressant effects, but how the drug shows its sustained effects is still a matter of controversy. The objectives were to evaluate the mechanisms for KET rapid (30 min) and long-lasting (15 and 30 days after) antidepressant effects in mice. A single dose of KET (2, 5, or 10 mg/kg, po) was administered to...
HRB Open Research
December 16, 2020
Bronagh Gallagher, Meabh Foley, C. Slattery et al.
6 citations
Background: Depression is a common psychiatric disorder that has become the leading cause of disability worldwide. The standard medical care for depression over the past 50 years has focused on monoamine neurotransmitters. These treatments can take weeks to take effect, highlighting the need for novel treatment strategies. One such approach may be ketamine. Ketamine acts as an antagonist of the...
Brain and Behavior
December 11, 2020
Lei Zou, S. Min, Qibin Chen et al.
We previously confirmed that low‐dose ketamine, as an adjunctive anesthetic for electroconvulsive therapy (ECT) in adult patients with depression, accelerates the effects of ECT and reduces the ECT‐induced learning and memory deficits. This study explored the efficacy and safety of low‐dose ketamine in elderly patients with depression.